Aytu Biopharma Inc SEC Filings

Reporting person: Jarrett Disbrow, Chief Business Officer and officer of AYTU BioPharma, Inc. (AYTU), reported equity grants on 10/03/2025. The filing shows two awards of restricted common stock issued at $0 per share: 19,606 shares granted as fully vested restricted stock in lieu of an annual cash bonus, and 12,500 shares granted as time‑based restricted stock.

The newly reported grants raise the reporting person’s total beneficial ownership to 61,568 shares. The time‑based award vests one‑third on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027

AYTU Biopharma (AYTU) Chief Financial Officer Ryan J. Selhorn reported two grants of restricted common stock on 10/03/2025. He received 16,243 fully vested shares paid in lieu of cash for his annual bonus and an additional 17,500 restricted shares that vest over time: 1/3 on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027. The grants were reported with a $0 purchase price, and following these transactions Mr. Selhorn beneficially owned 49,743 shares in total after the awards. The filing is signed by Mr. Selhorn on 10/07/2025.

Insider filing summary: The Form 4 shows that Joshua R. Disbrow, CEO and director of AYTU BioPharma (AYTU), received restricted common stock on 10/03/2025. He was granted 31,446 shares as fully vested restricted stock in lieu of his annual bonus and an additional 22,500 restricted shares that vest over time. After these grants his reported beneficial ownership rose to 207,203 shares.

The 22,500-share award vests 1/3 on 10/03/2026 with the remainder vesting in eight equal quarterly installments beginning 01/03/2027. Both grants had a reported price of $0, indicating they were awards rather than market purchases. The filing is signed by an attorney-in-fact on 10/07/2025.

Vivian H. Liu, a Director of AYTU BIOPHARMA, INC (AYTU), reported a restricted stock grant of $0 price common stock on 10/03/2025. The filing shows 10,000 shares were granted and will vest on 10/03/2026. After the grant Ms. Liu beneficially owns 19,825 shares. The transaction is reported on a Form 4 and was signed by an attorney-in-fact on 10/07/2025. The award is described as restricted stock with a one-year vesting date; no cash purchase price was paid for the granted shares.

Reporting person: Abhinav Jain, a director of AYTU BIOPHARMA, INC. (AYTU), reported a grant of 10,000 restricted shares on 10/03/2025. The restricted shares carry a vesting condition that they vest on 10/03/2026. The filing shows 19,500 shares beneficially owned by the reporting person after the transaction. The transaction is recorded as a non-derivative acquisition at a $0 price, consistent with a restricted stock grant. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/07/2025.

Carl C. Dockery, a director of AYTU BioPharma, Inc. (AYTU), reported the grant of 10,000 restricted shares on 10/03/2025. The award carries an exercise price of $0 and is scheduled to vest on 10/03/2026. After this grant, Mr. Dockery beneficially owns 20,440 shares in total. The Form 4 was signed by an attorney-in-fact on 10/07/2025. The filing indicates these are non‑derivative restricted stock awards rather than open-market purchases, which affects the timing of when the shares become tradable.

John A. Donofrio, Jr., a director of AYTU BioPharma, Inc. (AYTU), was granted 10,000 restricted shares on 10/03/2025. The grant carries a $0 per-share price and is described as restricted stock that vests on 10/03/2026.

Following the reported grant, the filing shows 13,762 shares beneficially owned by the reporting person. The Form 4 was signed on 10/07/2025 by an attorney-in-fact and includes a Power of Attorney exhibit.

Aytu BioPharma reported mixed 2025 results with strategic financing, asset impairments and a planned product launch. The company raised gross proceeds of $16.6 million in June 2025 through the sale of 2,806,688 common shares and 8,233,332 prefunded warrants; the prefunded warrants had an issuance fair value of approximately $12.3 million and $1.3 million of issuance costs were recorded in other (expense) income. In June 2025 the company recorded a $8.3 million impairment to product technology rights and also recognized a separate $2.7 million full impairment of other intangible assets. Aytu expects to launch EXXUA in the fourth calendar quarter of 2025 and capitalized commercialization rights with an estimated useful life through September 2030. Debt includes an amended Eclipse credit facility with $9.1 million outstanding on the revolving loan and an amended term loan (effective interest ~11.4%) after a $13.0 million increase; the company has a $100.0 million shelf registration with $100.0 million remaining available. The Consumer Health business was divested and is reported as discontinued operations.